Recent advances of IMiDs in cancer therapy

Current Opinion in Oncology

Volumn 22, Issue 6, 2010, Pages 579-585

  Li, Shirong ^a   Gill, Navkiranjit ^a   Lentzsch, Suzanne ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

chronic lymphocytic leukemia; immunomodulatory derivatives of thalidomide; multiple myeloma; non Hodgkin's lymphoma; stem cell mobilization

Indexed keywords

ACETYLSALICYLIC ACID; APRIL PROTEIN; AZACITIDINE; BORTEZOMIB; CD40 LIGAND; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; ERYTHROID KRUPPEL LIKE FACTOR; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR INDEPENDENCE 1B; LENALIDOMIDE; MELPHALAN; PANOBINOSTAT; PLERIXAFOR; POMALIDOMIDE; PREDNISONE; RAC1 PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RITUXIMAB; STROMAL CELL DERIVED FACTOR 1ALPHA; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR GATA 2; UNCLASSIFIED DRUG; WARFARIN;

ANEMIA; ANTICOAGULANT THERAPY; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLEEDING; BONE MARROW TOXICITY; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG MECHANISM; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE FUNCTION TEST; IMMUNOMODULATION; LEUKAPHERESIS; LOW DRUG DOSE; MANTLE CELL LYMPHOMA; MICROENVIRONMENT; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHODGKIN LYMPHOMA; OSTEOCLAST; OVERALL SURVIVAL; PLASMA CELL; PLEIOTROPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; STEM CELL MOBILIZATION; T LYMPHOCYTE; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOLOGIC FACTORS; THALIDOMIDE; TUMOR MICROENVIRONMENT;

EID: 77958514558     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32833d752c     Document Type: Review

References (47)

1. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immuno-modulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010; 24:22-32.
2. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009; 2:36.
3. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiplemyeloma through a LSD1-mediated epigenetic mechanism. Cancer Res2009; 69:7347-7356.
4. Keller M, SollbergerG, Beer HD. Thalidomide inhibits activation of caspase-1. J Immunol 2009; 183:5593-5599.
5. Xu Y, Li J, Ferguson GD, et al. Immunomodulatory drugs reorganize cytoske-leton by modulating Rho GTPases. Blood 2009; 114:338-345.
6. Breitkreutz I, Raab MS, Vallet S, et al. Lenalidomide inhibits osteoclastogen-esis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008; 22:1925-1932.
7. Lentzsch S, Gries M, Janz M, et al. Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 2003; 101:3568-3573.
8. Lapalombella R, Andritsos L, Liu Q, et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies bynormal B cells through a PI3-kinase-dependent pathway. Blood 2010;115:2619-2629.
9. Wei S, Chen X, Rocha K, et al. A critical role for phosphatase haplodeficiencyVerhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007; 67:746-755.
10. Koh KR, Janz M, Mapara MY, et al. Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. Blood 2005; 105:3833-3840.
11. Pal R, Monaghan SA, Hassett AC, et al. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood2010; 115:605-614.
12. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stemcell mobilization and engraftment postperipheral blood stem cell transplantationin patients with newly diagnosed myeloma. Leukemia 2007; 21:2035-2042.
13. Ximeri M, Galanopoulos A, Klaus M, et al. Effect of lenalidomide therapy onGalustian C, Dalgleish A. Lenalidomide: a novel anticancer drug with multiple modalities. Expert Opin Pharmacother 2009; 10:125-133.
14. Galustian C, Meyer B, Labarthe MC, et al. The anticancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009; 58:1033-1045.
15. Ramsay AG, Clear AJ, Kelly G, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide:implications for the tumor microenvironment and immunotherapy. Blood2009; 114:4713-4720.
16. Aue G, Njuguna N, Tian X, et al. Lenalidomide-induced upregulationof CD80on tumor cells correlates with T-cell activation, the rapid onset of a cytokine releasesyndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica 2009; 94:1266-1273.
17. Chan AC, Neeson P, Leeansyah E, et al. Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients. Leukemia 2010;24:592-600.
18. Ocio EM, Vilanova D, Atadja P, et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either borte-zomib or lenalidomide in multiple myeloma. Haematologica 2010; 95:794-803.
19. Zhang L, Qian Z, CaiZ, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 2009;84:553-559.
20. Lapalombella R, Yu B, Triantafillou G, et al. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 2008; 112:5180-5189.
21. Van Der Spek E, Bloem AC, Lokhorst HM, et al. Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma. Leuk Res 2009;33:100-108.
22. Liu P, Li J, Lu H, Xu B. Thalidomide inhibits leukemia cell invasion and migration by upregulation of early growth response gene 1. Leuk Lymphoma2009; 50:109-113.
23. Oliveira AM, Maria DA, Metzger M, et al. Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients. Leuk Res 2009; 33:970-973.
24. Palumbo A, Dimopoulos MA, Delforge M, et al. A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan andprednisone (MPR) in elderly patients with newly diagnosed multiple myeloma. Blood 2009; 114 [ASH Annual Meeting Abstract # 613].
25. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiplemyeloma: IFM 01/01 trial. J Clin Oncol 2009; 27:3664-3670.
26. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010 [Epub ahead of print].
27. 2) and autologoustransplantation (MEL200) in newly diagnosed myeloma patients J Clin Oncol2010; 28 [ASCO Annual Meeting, Abstract 8015].
28. McCarthy PL, Owzar K, Stadtmauer EA, et al. Phase III intergroup study of lenalidomide (CC-5013) versus placebo maintenance therapyfollowing single autologous stem cell transplant for multiple myeloma (CALGB 100104): initial report of patient accrual and adverse events. American Society of Hematology Annual Meeting 2009 [Abstract# 3416].
29. Moreau P, Facon T, and Attal, M. Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (VTD) to bortezomib plus dexametha-son (VD) as induction treatment prior to ASCT in de novo multiple myeloma(MM): results of IFM2007-02 study. J Clin Oncol 2010; 28 [ASCO AnnualMeeting Abstract 8014].
30. Knop S, Gerecke C, Liebisch P, et al. Lenalidomide, adriamycin, and dex-amethasone (RAD) in patients with relapsed and refractory multiple myeloma:a report from the German Myeloma Study Group DSMM (Deutsche Studien-gruppe Multiples Myelom). Blood 2009; 113:4137-4143.
31. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol2009; 27:5008-5014.
32. Mateos M-V, Lopez-Corral L, Hernandez MT, et al. Multicenter, randomized, open-label, phase III trial of lenalidomide-dexamethasone (Len/dex) vs. therapeutic abstention in smoldering multiple myeloma at high risk of progressionto symptomatic MM: results of the first interim analysis. Am Soc Hematol AnnMeeting 2009 [Abstract # 614].
33. Ades L, Boehrer S, Prebet T, et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion:results of a phase 2 study. Blood 2009; 113:3947-3952.
34. Sekeres MA, List AF, Cuthbertson D, et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplasticsyndromes. J Clin Oncol 2010; 28:2253-2258.
35. Passamonti F, Gattoni E, Cervantes F, et al. Pomalidomide therapy in myelofibrosis: 2-year follow-up of a randomized phase 2 study. Am SocHematol Ann Meeting 2009 [Abstract # 1904].
36. Veliz M, Santana R, Lancet JE, et al. Phase II study of lenalidomide in combination with rituximab for patients with CD5+/CD20+ hematologicmalignancies who relapse or progress after rituximab. Interim AnalysisAmerican Society of Hematology Annual Meeting 2009 [Abstract# 2376].
37. Ferrajoli A, Badoux XC, O'Brien S, et al. Combination therapy with lenalido-mide and rituximab in patients with relapsed chronic lymphocytic leukemia(CLL). American Society of Hematology Annual Meeting 2009 [Abstract #206].
38. Brown JR, Abramson JS, Hochberg EP, et al. A phase I study of lenalidomide in combination with fludarabine-rituximab in previously untreatedCLL/SLL. American Society of Hematology Annual Meeting 2009 [Abstract# 3426].
39. Fowler NH, McLaughlin P, Kwak L, et al. Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma. J Clin Oncol 2009; 27:15s
40. Fowler N, McLaughlin P, Hagemeister FB, et al. A biologic combination of lenalidomide and rituximab for front-line therapy of indolent B-cell non-Hodgkin's lymphoma. American Society of Hematology Annual Meeting[Abstract # 1714].
41. Dutia M, DeRoock I, Chee K, et al. Preliminary results of a phase II study of lenalidomide and rituximab in relapsed/refractory indolent non-Hodgkin'slymphoma (NHL). American Society of Hematology Annual Meeting 2009[Abstract # 1679].
42. Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin'slymphoma. J Clin Oncol 2009; 27:5404-5409.
43. Czuczman MS, Vose J, Zinzani P, et al. Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-celllymphoma: results from an international study (NHL-003). J Clin Oncol 2009; 27 [ASCO Annual Meeting]
44. Reeder CB, Witzig TE, Zinzani PL, et al. Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma:results from an international study (NHL-003). J Clin Oncol 2009; 27:15s
45. ASCO Annual Meeting, Abstract # 8569.Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantlecell lymphoma. Br J Haematol 2009; 145:344-349.
46. Palumbo A, Cavo M, Bringhen S, et al. A phase III study of enoxaparin vs. aspirin vs. low-dose warfarin as thromboprophylaxis for newly diagnosedmyeloma patients treated with thalidomide based-regimens. American Society of Hematology Annual Meeting 2009 [Abstract # 492].
47. Kumar S, Giralt S, Stadtmauer EA, et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapywith thalidomide, lenalidomide or bortezomib-containing regimens. Blood2009; 114:1729-1735.